Wall Street Breakfast Podcast: Markets Smell A Deal In D.C.

view original post

Getty Images

Listen below or on the go via Apple Podcasts and Spotify

Stock index futures jump on reports of Senate breakthrough to end shutdown. (00:19) Taiwan Semi’s (TSM) October revenue rises 17% YoY, below September’s surge. (01:50) Rumble (RUM) to buy German AI firm Northern Data (OTC:NDTAF) for $767 million in an all-stock transaction. (02:46)

This is an abridged transcript.

Futures are in the green this morning as a deal to reopen the government has passed a procedural vote in the Senate.

Dow futures (INDU) +0.5%, S&P futures (SPX) +1%, and Nasdaq futures (US100:COMP) +1.6%. Bitcoin (BTC-USD) +1.6% and above $106,000.

In a 60-40 vote with seven democrats and one independent voting alongside republicans, the late Sunday night vote paved the way for the government to reopen.

The Senate needs a formal vote and the House will also need to return and pass the measure before the president signs it.

The stopgap deal includes funding for several departments through the end of the fiscal year, while extending funding for other agencies through Jan. 30. The plan would also provide back pay for furloughed workers and resume suspended federal payments to states and localities.

The main sticking point, the reason for the shutdown, ACA subsidies. This deal does not guarantee an extension of those credits.

Deutsche Bank’s Jim Reid said, “Once the government reopens, markets will face a surge of delayed data releases. Historical precedent from the 2013 shutdown suggests that September’s employment report could be among the first to hit the wires, potentially within three business days of reopening.”

UBS’ Paul Donovan said, “Normally when shutdowns end, the economy bounces back to compensate for the drag on growth in the shutdown, though this time there may be more lingering damage.”

Taiwan Semiconductor Manufacturing’s (TSM) October revenue rose 16.9% year-on-year, the slowest pace since February 2024, and was lower than the 39.6% surge in September.

TSM — which produces chips for some of the world’s largest tech companies, including Apple (AAPL), Nvidia (NVDA), and AMD (AMD)—saw October revenue of NT$367.47 billion.

Analysts on average are expecting TSMC sales to increase 16% in the current quarter, according to a report by Bloomberg News.

Month-over-month, TSM’s revenue rose 11%, and it’s up 33.8% for January–October 2025.

Shares in the world’s largest contract chipmaker, have gained about 45% since the beginning of this year.

Nvidia (NVDA) CEO Jensen Huang said on Saturday that he has asked for additional chip supplies from Taiwan Semiconductor Manufacturing Company (TSM) as the demand for artificial intelligence remains strong.

Video platform Rumble (RUM) is set to acquire German AI cloud company Northern Data (OTC:NDTAF).

The all-stock deal is valued at about $767 million.

Northern Data shareholders will receive 2.0281 newly issued Class A shares of Rumble per Northern Data share.

The deal includes a $150 million GPU leasing agreement with cryptocurrency firm Tether, which owns 48% of Rumble, and $200 million in tax liability support from Rumble.

The deal is expected to close by Q2 2026.

Rumble (RUM) is up 17% in premarket action.

What’s Trending on Seeking Alpha:

SA Asks: What are the best AI-focused ETFs right now?

Duffy: Air travel will slow to a ‘trickle’ ahead of Thanksgiving if shutdown persists

Tesla’s Cybertruck head quits after eight years

Dow, S&P and Nasdaq futures are in the green. Crude oil is up 0.8% at $60/barrel. Gold is up 2% at $4,078.

The FTSE 100 is up 1% and the DAX is up 1.8%.

The biggest movers for the day premarket: Metsera (MTSR) -15% – Shares plunged after Novo Nordisk (NVO) said it will not raise its takeover bid, clearing the way for Pfizer (PFE) to win the acquisition battle. Metsera announced a revised merger agreement with Pfizer valued at up to $86.25 per share in cash, citing the deal as superior due to increasing antitrust risks tied to Novo’s competing offer. The agreement ends a tense bidding war between the two drugmakers over the weight-loss biotech.

Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.